BWI: Sun Pharma Announces USFDA Tentative Approval for Generic Stalevo®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Friday, October 01, 2010 05:30 PM IST (12:00 PM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
--------------------------------------------------
Sun Pharma Announces USFDA Tentative Approval for Generic Stalevo®


Mumbai, Maharashtra, India, Friday, October 01, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion's Stalevo® tablets.

These generic Carbidopa, Levodopa and Entacapone tablets contain Carbidopa, Levodopa and Entacapone 25/100/200 mg, and 37.5/150/200 mg.

Generic Carbidopa, Levodopa and Entacapone tablets are indicated in the treatment of Parkinson's disease.

These strengths of Stalevo® have annual sales of approximately $ 95 million in the US.

®Manufactured by Orion Corporation.
Marketed by Novartis

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.


CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 (22) 6645 5645, Xtn 605/ +91 9867010529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Xtn 606/ +91 9821923797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com